MAIA RSI Chart
Last 7 days
6.2%
Last 30 days
65.1%
Last 90 days
109.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 25, 2024 | smith stan | bought | 299,409 | 2.03 | 147,492 | - |
Apr 25, 2024 | louie ngar yee | bought | 39,919 | 2.03 | 19,665 | - |
Mar 14, 2024 | luput cristian | bought | 81,059 | 1.17 | 69,282 | - |
Mar 14, 2024 | louie ngar yee | bought | 200,000 | 1.17 | 170,940 | - |
Mar 14, 2024 | guerrero ramiro | bought | 8,105 | 1.17 | 6,928 | - |
Mar 14, 2024 | chaouki steven m | bought | 40,530 | 1.17 | 34,641 | - |
Mar 14, 2024 | smith stan | bought | 200,000 | 1.17 | 170,940 | - |
May 18, 2023 | guerrero ramiro | bought | 2,964 | 2.47 | 1,200 | - |
May 15, 2023 | luput cristian | bought | 7,890 | 2.63 | 3,000 | - |
Apr 28, 2023 | vitoc vlad | bought | 10,000 | 2.5 | 4,000 | chief executive officer |
Which funds bought or sold MAIA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 55,143 | 55,143 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 21,939 | 46,860 | -% |
May 15, 2024 | MORGAN STANLEY | added | 98.14 | 16,248 | 22,209 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -9.00 | - | -% |
May 15, 2024 | SABBY MANAGEMENT, LLC | sold off | -100 | -152,697,000 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 57.62 | 8,258 | 12,463 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -39.63 | 11,971 | 100,540 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -81.08 | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -58.68 | -14,995 | 52,248 | -% |
May 14, 2024 | NORTHERN TRUST CORP | unchanged | - | 20,882 | 44,601 | -% |
Peers (Alternatives to MAIA Biotechnology, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
MAIA Biotechnology, Inc. News
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | 15.2% | 8,716 | 7,567 | 7,001 | 10,269 | 9,074 | 12,022 | 14,783 | 9,760 | 10,543 | 11,327 | 747 |
Current Assets | 15.0% | 8,700 | 7,564 | 6,633 | 9,776 | 8,334 | 11,808 | 14,780 | 8,610 | - | 10,672 | 747 |
Cash Equivalents | 15.7% | 8,271 | 7,151 | 6,105 | 9,146 | 7,586 | 10,951 | 14,064 | 8,150 | 10,293 | 10,574 | 663 |
Liabilities | 104.3% | 14,481 | 7,089 | 4,253 | 3,394 | 3,991 | 3,514 | 2,672 | 3,098 | 2,622 | 2,146 | 2,363 |
Current Liabilities | -0.6% | 4,908 | 4,937 | 4,150 | 3,273 | 3,766 | 3,269 | 2,456 | 3,098 | - | 2,146 | 1,694 |
Shareholder's Equity | -1307.3% | -5,764 | 478 | 2,748 | 6,874 | 5,083 | 8,508 | 12,111 | 6,662 | 9,014 | 9,181 | - |
Retained Earnings | -12.6% | -72,047 | -63,980 | -57,723 | -52,847 | -48,324 | -44,207 | -40,061 | -35,157 | - | -28,437 | -15,934 |
Additional Paid-In Capital | 2.9% | 66,311 | 64,472 | 60,514 | 59,747 | 53,432 | 52,730 | 52,223 | 41,823 | - | 37,618 | 12,600 |
Shares Outstanding | 17.8% | 20,003 | 16,986 | 13,761 | 13,648 | 10,996 | 10,956 | 8,714 | 8,197 | 7,752 | 7,585 | 4,434 |
Float | - | - | - | - | 22,484 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Cashflow From Operations | 10.2% | -3,586 | -3,992 | -3,157 | -2,560 | -3,360 | -2,949 | -4,319 | -2,019 | -2,807 | -1,607 | -1,311 | - | - |
Share Based Compensation | -74.3% | 350 | 1,362 | 571 | 619 | 538 | 489 | 532 | 585 | 713 | 614 | 779 | - | - |
Cashflow From Financing | -6.1% | 4,717 | 5,025 | 126 | - | - | -192 | 10,259 | -120 | 2,531 | 1,229 | 5,483 | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development expenses | $ 2,320,742 | $ 2,195,991 |
General and administrative expenses | 1,628,134 | 1,988,259 |
Total operating expenses | 3,948,876 | 4,184,250 |
Loss from operations | (3,948,876) | (4,184,250) |
Other (expense) income: | ||
Interest expense | (5,147) | |
Interest income | 44,118 | 336 |
Australian research and development incentives | 18,601 | 51,243 |
Change in fair value of warrant liability | (4,181,298) | 20,942 |
Other income, net | (4,118,579) | 67,374 |
Net loss | (8,067,455) | (4,116,876) |
Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (8,067,455) | $ (4,116,876) |
Net loss per share | ||
Net loss per share basic | $ (0.46) | $ (0.38) |
Net loss per share diluted | $ (0.46) | $ (0.38) |
Weighted average common shares outstanding basic | 17,601,407 | 10,977,054 |
Weighted average common shares outstanding diluted | 17,601,407 | 10,977,054 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 8,271,449 | $ 7,150,695 |
Prepaid expenses and other current assets | 272,583 | 268,677 |
Australia research and development incentives receivable | 155,969 | 144,680 |
Total current assets | 8,700,001 | 7,564,052 |
Deferred offering costs | 13,235 | 0 |
Other assets | 2,800 | 2,800 |
Total assets | 8,716,036 | 7,566,852 |
Current liabilities: | ||
Accounts payable | 1,872,502 | 1,638,546 |
Accrued expenses | 3,035,265 | 3,298,607 |
Total current liabilities | 4,907,767 | 4,937,153 |
Long term liabilities: | ||
Warrant liability | 9,573,197 | 2,152,188 |
Total liabilities | 14,480,964 | 7,089,341 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity (deficit) | ||
Preferred stock, $0.0001 par value, 30,000,000 shares authorized at March 31, 2024 and December 31, 2023, 0 shares issued and outstanding | ||
Common stock, $0.0001 par value, 70,000,000 shares authorized at March 31, 2024 and December 31, 2023, 20,581,469 and 16,986,254 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2,059 | 1,699 |
Additional paid-in capital | 66,310,691 | 64,472,249 |
Accumulated deficit | (72,047,632) | (63,980,177) |
Accumulated other comprehensive loss | (30,046) | (16,260) |
Total stockholders' equity (deficit) | (5,764,928) | 477,511 |
Total liabilities and stockholders' equity (deficit) | $ 8,716,036 | $ 7,566,852 |